Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

US9890207B2 · kind B2 · utility

Assignees

• CALIFORNIA INSTITUTE OF TECHNOLOGY · US
• The Rockefeller University · US

Inventors

• Ron Diskin · Rehovot, IL
• Pamela J. Bjorkman · Altadena, US
• Michel Nussenzweig · New York, US
• Johannes Scheid · New York, US

Key dates

• Filing date: Jul 25, 2012
• Grant date: Feb 13, 2018
• Expiry date: Jul 25, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16111
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.